ReviewJournal of endocrinological investigation2012
The cardiovascular system in growth hormone excess and growth hormone deficiency.
Review in Journal of endocrinological investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- A case-control study coupling with meta-analysis elaborates decisive association betweenAging · 2023Pooled it
- New insights on the cardiovascular effects of IGF-1.Frontiers in endocrinology · 2023Pooled it
- MRI Assessment of Cardiac Function and Morphology in Adult Patients With Growth Hormone Deficiency: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2022Pooled it
- Acromegaly and cardiovascular disease: mechanisms, clinical impact, and evolving management.Endocrine reviews · 2026Review
- Circulating Asprosin Declines During 24 Months of Growth Hormone Replacement and Is Associated with IGF-1 and Metabolic Remodeling in Adults with Growth Hormone Deficiency.International journal of molecular sciences · 2026Article
- A helical peptide antagonist of the human growth hormone receptor.Endocrinology · 2026Article
- Twenty-Four-Month rhGH Intervention: Insights into Redox Regulation, Vascular Biomarkers, and Body Composition in Adult GHD Patients.International journal of molecular sciences · 2026Article
- Mechanisms of aging in the cardiovascular system: challenges and opportunities.Frontiers in immunology · 2025Review
- Diastolic Dysfunction with Normal Ejection Fraction and Reduced Heart Rate in Mice Expressing Human Growth Hormone and Displaying Signs of Growth Hormone Insufficiency.International journal of molecular sciences · 2024Article
- Article
- Article
- The spectrum of cardiac abnormalities in patients with acromegaly: results from a case-control cardiac magnetic resonance study.Pituitary · 2024Article
- The Double-Edged Sword of Total Antioxidant Capacity: Clinical Significance and Personal Experience.Antioxidants (Basel, Switzerland) · 2024Review
- Normal or improved cardiovascular risk factors in IGF-I-deficient adults with growth hormone receptor deficiency.Med (New York, N.Y.) · 2024Article
- Increased levels of plasma neudesin in adult growth hormone deficiency and their relationship with plasma liver-expressed antimicrobial peptide-2 levels: a cross-sectional study.Journal of endocrinological investigation · 2023Article
- Cardiovascular Effects of Excess Growth Hormone: How Real is the Threat?Reviews in cardiovascular medicine · 2023Review
- Short and long-term associations between serum proteins linked to cardiovascular disease and particle exposure among constructions workers.Scandinavian journal of work, environment & health · 2023Article
- Mediterranean Diet and Obesity-related Disorders: What is the Evidence?Current obesity reports · 2022Review
- [Cardiovascular complications associated with acromegaly. A state-of-the-art].Archivos de cardiologia de Mexico · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical conditions associated with GH excess and GH deficiency (GHD) are known to be associated with an increased risk for the cardiovascular morbidity and mortality, suggesting that either an excess or a deficiency in GH and/or IGF-I is deleterious for cardiovascular system. In patients with acromegaly, chronic GH and IGF-I excess commonly causes a specific cardiomyopathy characterized by a concentric cardiac hypertrophy associated with diastolic dysfunction and, in later stages, with systolic dysfunction ending in heart failure if GH/IGF-I excess is not controlled. Abnormalities of cardiac rhythm and anomalies of cardiac valves can also occur. Moreover, the increased prevalence of cardiovascular risk factors, such as hypertension, diabetes mellitus, and insulin resistance, as well as dyslipidemia, confer an increased risk for vascular atherosclerosis. Successful control of the disease is accompanied by a decrease of the cardiac mass and improvement of cardiac function and an improvement in cardiovascular risk factors. In patients with hypopituitarism, GHD has been considered the under- lying factor of the increased mortality when appropriate standard replacement of the pituitary hormones deficiencies is given. Either childhood-onset or adulthood-onset GHD are characterized by a cluster of abnormalities associated with an increased cardiovascular risk, including altered body composition, unfavorable lipid profile, insulin resistance, endothelial dysfunction and vascular atherosclerosis, a decrease in cardiac mass together with an impairment of systolic function mainly after exercise. Treatment with recombinant GH in patients with GHD is followed by an improvement of the cardiovascular risk factors and an increase in cardiac mass together with an improvement in cardiac performance. In conclusion, acromegaly and GHD are associated with an increased risk for cardiovascular morbidity and mortality, but the control of GH/IGF-I secretion reverses cardiovascular abnormalities and restores the normal life expectancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.